Charles Schwab Investment Management Inc Bluebird Bio, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 553,060 shares of BLUE stock, worth $176,979. This represents 0.0% of its overall portfolio holdings.

Number of Shares
553,060
Previous 554,183 0.2%
Holding current value
$176,979
Previous $543,000 47.15%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$0.47 - $1.35 $527 - $1,516
-1,123 Reduced 0.2%
553,060 $287,000
Q2 2024

Aug 12, 2024
BUY
$0.85 - $1.26 $26,966 - $39,973
31,725 Added 6.07%
554,183 $543,000
Q1 2024

May 08, 2024
BUY
$0.91 - $1.75 $207,897 - $399,803
228,459 Added 77.71%
522,458 $668,000
Q4 2023

Feb 06, 2024
BUY
$1.32 - $4.83 $3,033 - $11,099
2,298 Added 0.79%
293,999 $405,000
Q3 2023

Nov 08, 2023
SELL
$3.02 - $4.05 $1,066 - $1,429
-353 Reduced 0.12%
291,701 $886,000
Q2 2023

Aug 09, 2023
BUY
$2.79 - $5.03 $163,979 - $295,633
58,774 Added 25.19%
292,054 $960,000
Q1 2023

May 11, 2023
BUY
$3.14 - $8.22 $34,455 - $90,198
10,973 Added 4.94%
233,280 $741,000
Q4 2022

Feb 13, 2023
BUY
$5.77 - $8.49 $127,886 - $188,172
22,164 Added 11.07%
222,307 $1.54 Million
Q3 2022

Nov 14, 2022
BUY
$3.75 - $7.39 $37,856 - $74,602
10,095 Added 5.31%
200,143 $1.27 Million
Q2 2022

Aug 15, 2022
BUY
$2.94 - $5.23 $23,852 - $42,430
8,113 Added 4.46%
190,048 $787,000
Q1 2022

May 13, 2022
BUY
$4.07 - $10.6 $19,951 - $51,961
4,902 Added 2.77%
181,935 $883,000
Q4 2021

Feb 11, 2022
BUY
$8.96 - $16.31 $65,175 - $118,638
7,274 Added 4.28%
177,033 $1.77 Million
Q3 2021

Nov 16, 2021
SELL
$11.24 - $21.0 $3.17 Million - $5.92 Million
-281,920 Reduced 62.42%
169,759 $3.25 Million
Q2 2021

Aug 16, 2021
BUY
$18.04 - $22.09 $2.59 Million - $3.17 Million
143,294 Added 46.47%
451,679 $14.4 Million
Q1 2021

May 17, 2021
SELL
$16.59 - $33.89 $317,565 - $648,722
-19,142 Reduced 5.84%
308,385 $9.3 Million
Q4 2020

Feb 16, 2021
BUY
$27.5 - $37.92 $129,910 - $179,134
4,724 Added 1.46%
327,527 $14.2 Million
Q3 2020

Nov 13, 2020
BUY
$34.44 - $43.75 $342,746 - $435,400
9,952 Added 3.18%
322,803 $17.4 Million
Q2 2020

Aug 14, 2020
BUY
$27.12 - $45.97 $1.37 Million - $2.32 Million
50,401 Added 19.2%
312,851 $19.1 Million
Q1 2020

May 15, 2020
BUY
$26.16 - $63.5 $106,942 - $259,588
4,088 Added 1.58%
262,450 $12.1 Million
Q4 2019

Feb 07, 2020
BUY
$46.96 - $61.67 $176,146 - $231,324
3,751 Added 1.47%
258,362 $22.7 Million
Q3 2019

Nov 08, 2019
BUY
$59.47 - $93.1 $774,715 - $1.21 Million
13,027 Added 5.39%
254,611 $23.4 Million
Q2 2019

Aug 09, 2019
BUY
$75.84 - $105.21 $576,839 - $800,227
7,606 Added 3.25%
241,584 $30.7 Million
Q1 2019

May 14, 2019
BUY
$64.44 - $104.11 $1.11 Million - $1.79 Million
17,220 Added 7.94%
233,978 $36.8 Million
Q4 2018

Feb 14, 2019
BUY
$59.1 - $93.26 $627,405 - $990,048
10,616 Added 5.15%
216,758 $21.5 Million
Q3 2018

Nov 13, 2018
SELL
$88.86 - $117.49 $5.09 Million - $6.73 Million
-57,321 Reduced 21.76%
206,142 $30.1 Million
Q2 2018

Aug 08, 2018
SELL
$99.64 - $127.59 $6.88 Million - $8.81 Million
-69,073 Reduced 20.77%
263,463 $41.4 Million
Q1 2018

May 07, 2018
BUY
$105.8 - $150.94 $3.86 Million - $5.5 Million
36,463 Added 12.32%
332,536 $56.8 Million
Q4 2017

Jan 17, 2018
BUY
$81.25 - $130.7 $2.39 Million - $3.84 Million
29,380 Added 11.02%
296,073 $52.7 Million
Q3 2017

Nov 13, 2017
BUY
$57.74 - $91.42 $15.4 Million - $24.4 Million
266,693
266,693 $36.6 Million

Others Institutions Holding BLUE

# of Institutions
152
Shares Held
63.7M
Call Options Held
264K
Put Options Held
428K
View Full List

About bluebird bio, Inc.

BLUE Quotes by TradingView
  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $24.7M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email